Growth Hormone Doping in Sports: A Critical Review of Use and Detection Strategies
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
GH is believed to be widely employed in sports as a performance-enhancing substance. Its use in athletic competition is banned by the World Anti-Doping Agency, and athletes are required to submit to testing for GH exposure. Detection of GH doping is challenging for several reasons including identity/similarity of exogenous to endogenous GH, short half-life, complex and fluctuating secretory dynamics of GH, and a very low urinary excretion rate. The detection test currently in use (GH isoform test) exploits the difference between recombinant GH (pure 22K-GH) and the heterogeneous nature of endogenous GH (several isoforms). Its main limitation is the short window of opportunity for detection (~12-24 h after the last GH dose). A second test to be implemented soon (the biomarker test) is based on stimulation of IGF-I and collagen III synthesis by GH. It has a longer window of opportunity (1-2 wk) but is less specific and presents a variety of technical challenges. GH doping in a larger sense also includes doping with GH secretagogues and IGF-I and its analogs. The scientific evidence for the ergogenicity of GH is weak, a fact that is not widely appreciated in athletic circles or by the general public. Also insufficiently appreciated is the risk of serious health consequences associated with high-dose, prolonged GH use. This review discusses the GH biology relevant to GH doping; the virtues and limitations of detection tests in blood, urine, and saliva; secretagogue efficacy; IGF-I doping; and information about the effectiveness of GH as a performance-enhancing agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
IRANMANESH, A., LIZARRALDE, G., & VELDHUIS, J. D. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1081 · Cited by 672
Ho, K. Y., Veldhuis, J. D., Johnson, M. L., Furlanetto, R., Evans, W. S., Alberti, K. G., & Thorner, M. O. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113450 · Cited by 503
Nass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Harrell, F. E., Clasey, J. L., Heymsfield, S. B., Bach, M. A., Vance, M. L., & Thorner, M. O. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-9-200811040-00003 · Cited by 255
Meinhardt, U., Nelson, A. E., Hansen, J. L., Birzniece, V., Clifford, D., Leung, K.-C., Graham, K., & Ho, K. K. Y. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-9-201005040-00007 · Cited by 127
Laboratory measurement of growth hormone
Popii, V., & Baumann, G. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.06.007 · Cited by 100
Self-citation
Cited by
Pope, H. G., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., & Bhasin, S. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1058 · Cited by 658
Recent advances in high-sensitivity detection methods for paper-based lateral-flow assay
Nguyen, V.-T., Song, S., Park, S., & Joo, C. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112015 · Cited by 373
Yuen, K. C. J., Biller, B. M. K., Radovick, S., Carmichael, J. D., Jasim, S., Pantalone, K. M., & Hoffman, A. R. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0405 · Cited by 298
Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement
Reed, M. L., Merriam, G. R., & Kargi, A. Y. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00064 · Cited by 119
Use of Performance-Enhancing Substances
LaBotz, M., Griesemer, B. A., COUNCIL ON SPORTS MEDICINE AND FITNESS, Brenner, J. S., LaBella, C. R., Brooks, M. A., Diamond, A., Kelly, A. K. W., LaBotz, M., Logan, K., et al. (2016) · Pediatrics · doi:10.1542/peds.2016-1300 · Cited by 79
Metadata
- Authors
- Baumann, G. P.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2012-02-24
- Volume
- 33
- Issue
- 2
- Pages
- 155-186
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2023055302
- Cited by
- 116
- References
- 6
- FWCI
- 41.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.